REFERENCES
- De Pauw BE, Kauw F, Muytjens H, Bothof Th. Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J Antimicrob Chemother 1983; 12 Suppl A: 93–9.
- De Pauw BE, Boogaerts MA, Demuynck H, Mestdagh N, Verbist L, Goldstone AH, et al. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185–200.
- Ljungberg B, Nilsson-Ehle I. Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients. Eur J Clinical Pharmacol 1988; 34: 173–8.
- Ljungberg B, Nilsson-Ehle I. Advancing age and acute infection influence the kinetics of ceftazidime. Scand J Infect Dis 1989; 21: 327–32.
- Nyhlen A, Ljunberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem in febrile neutropenic patients. Eur J Clin Microbiol Infect Dis 1997; 16: 797–802.
- Krutzén E, Bäck SE, Nilsson-Ehle I, Nilsson-Ehle P. Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med 1984; 104: 955–61.
- Ljungberg B, Nilsson-Ehle I. Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males. Eur J Clin Pharmacol 1988; 34: 179–86.
- Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. Philadelphia PA: Lea & Febiger, 1991: 14–23.
- Bäck SE, Ljungberg B, Nilsson-Ehle I, Borgå O, Nilsson-Ehle P. Age dependence of renal function: clearance of iohexol and p-amino hippurate in healthy males. Scand J Clin Lab Invest 1989; 49: 641–6.
- Granerus G, Aurell M. Reference values for 51Cr-EDTA as a measure of GFR. Scand J Clin Lab Invest 1981; 41: 611–6.
- Dholakia N, Rolston KVI, Ho DH. In vitro activity of FK-037, a novel cephalosporin, against bacterial isolates from neutropenic patients. Eur J Clin Microbiol Infect Dis 1994; 13: 679–85.
- Gomez CMH, Cordingly JJ, Palazzo MGA. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999; 43: 1798–802.
- Drusano G. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand J Infect Dis 1991; Suppl 74: 235–48.
- SAS Institute, Cary, NC, USA.
- Kovarik J, Rozenberg-Arska M, Visser M, Verhoef J. Pharmacodynamics of cefepime. Scand J Infect Dis 1991; Suppl 74: 270–3.
- Rains CP, Bryson HM, Peters DH. Ceftazidime, an update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1995; 49: 577–617.
- Craig WA, Cars O. General discussion on antibiotic dosing. Scand J Infect Dis 1991; Suppl 74: 282–3.
- Daenen S, Erjavec Z, Uges DRA, De Vries-Hospers HG, De Jonge P, Halie MR. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 1995; 14: 188–92.
- Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67: 608–16.